Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + Pembrolizumab in Relapsed/Refractory Lymphomas
NCT07283822Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), Hodgkin lymphoma (HL), gray zone lymphoma (GZL), primary mediastinal large B-cell lymphoma (PMBCL). Started Dec 2025; status: recruiting.
02
Drugs
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)Hodgkin lymphoma (HL)gray zone lymphoma (GZL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT07283822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283822.